Therapy News and Research

RSS

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

A new type of breast cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Positron comments on new medical radiation bill passed into law in California

Positron Corporation, a leading molecular imaging company specializing in the field of nuclear cardiology, commented on the new medical radiation bill passed into law in California.

8 Oct 2010

Cincinnati Children's Hospital Medical Center named Centers of Excellence for Molecular Hematology

Cincinnati Children's Hospital Medical Center has been named one of five national Centers of Excellence for Molecular Hematology to find new gene and cell therapies for inherited diseases affecting blood cells.

8 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed U.S. physicians with regard to their treatment of skin and skin structure infections.

8 Oct 2010

Low-fat diet reduces risk of heart disease

Losing weight, especially among adults who are very heavy to obese, is a good way to prevent the onset of atherosclerosis, the artery-thickening condition that leads to potentially deadly heart disease. A diet that is low in either fats or carbohydrates can help reduce weight. But which one is the more heart-healthy?

8 Oct 2010

IV ibuprofen effective in reducing fever in hospitalized patients

Cumberland Pharmaceuticals Inc. today announced the publication of data affirming the safety and efficacy of Caldolor (ibuprofen) Injection in treating fever in critically ill and non-critically ill adults. Published in the peer-reviewed journal Critical Care, the study showed that IV ibuprofen was significantly more effective at reducing fever in hospitalized patients than placebo.

8 Oct 2010

Vanderbilt-Ingram Cancer Center receives $7.6M ARRA stimulus grant for prostate cancer research

Vanderbilt-Ingram Cancer Center has received a $7.6 million American Recovery and Reinvestment Act of 2009 stimulus grant to coordinate a study comparing the effectiveness of various treatments for prostate cancer. David Penson, M.D., M.P.H., professor of Urologic Surgery, will serve as Principal Investigator for the Comparative Effectiveness Analysis of Surgery and Radiation study on prostate cancer.

8 Oct 2010

Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels

Spherix Incorporated, an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its Phase 3 study of D-tagatose as a monotherapy in Type 2 diabetes showed a statistically significant (p<0.05) reduction in HbA1c levels of 0.4% at 10 months in relatively healthy people with diabetes

8 Oct 2010

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

The way melanoma cells use the immune system to spread and develop into lung tumors may lead to a therapy to decrease development of these tumors, according to Penn State researchers.

8 Oct 2010

Intestinal bacteria send signals that promote cell proliferation in Wnt signaling pathway

Microbes matter -- perhaps more than anyone realizes -- in basic biological development and, maybe, they could be a target for reducing cancer risks, according to University of Oregon researchers.

8 Oct 2010

Novel peptide NX002 demonstrates efficacy in animal model of oral mucositis: Study

NephRx Corporation today announced that a new study has shown that its novel peptide NX002 demonstrated significant efficacy when tested in an animal model of oral mucositis. Mucositis is a debilitating and often dose-limiting side effect of many forms of cancer therapy that affects more than 400,000 patients who receive chemotherapy or radiation treatment in the U.S. each year. Current treatment options are very limited.

8 Oct 2010

New imaging technique may help in early detection of prostate cancer

Prostate cancer -- the most common cancer afflicting American men -- may be effectively diagnosed at an early stage without ionizing radiation, using a non-invasive imaging technique known as contrast-enhanced ultrasound (CEUS), according to a report announced late last week at the 25th Annual Advances in Contrast Ultrasound - ICUS Bubble Conference in Chicago.

8 Oct 2010

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

Genzyme Corp. announced today that its board of directors has voted unanimously to reject the unsolicited $69.00 per share tender offer from Sanofi-Aventis, and the board recommends that Genzyme shareholders not tender their shares to Sanofi-Aventis pursuant to the offer.

8 Oct 2010

Websites bridge gaps between patients and doctors and marketers

Conveying how well a therapy works and doing so in understandable terms isn't easy, but a group of physicians is trying to change that The Wall Street Journal's Health Blog reports.

8 Oct 2010

Parkinson’s disease pathology breakthrough

Researchers have found that brain cells of people with early Parkinson's disease have damaged powerhouses. In a new study they have identified 10 groups of gene sets related to the energy production problems in the brain cells of these people.

8 Oct 2010

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Advanced Medical Isotope Corporation, a company engaged in the production and distribution of medical isotopes, is delighted to announce the execution of an exclusive world-wide license for patented technology for a proprietary brachytherapy seed with a fast-dissolving matrix for optimized delivery of radionuclides to cancer tissue.

7 Oct 2010

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

7 Oct 2010

Cs-131 brachytherapy seed implant can treat metastasized cancer

IsoRay, Inc. announced today another milestone in the use of Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy). Doctors at a world renowned medical facility have performed the world's first Cs-131 brachytherapy seed implant following a wedge resection of a lung tumor which originated from a form of malignant uterine cancer. Initially used to treat primary cancers, Cs-131 seeds are now being used to treat metastasized cancer.

7 Oct 2010

Study shows radioembolisation with TheraSphere effective for primary liver cancer

MDS Nordion, a leading provider of products and services to the global health science market, today announced that the first large European study using Yttrium-90 (Y-90) glass microspheres has been published on the use of TheraSphere, an innovative radioembolisation therapy for the localised treatment of patients with advanced hepatocellular carcinoma (HCC) or primary liver cancer.

7 Oct 2010

Therapy News and Research

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

Positron comments on new medical radiation bill passed into law in California

Cincinnati Children's Hospital Medical Center named Centers of Excellence for Molecular Hematology

Abiraterone Phase III clinical data to be presented at ESMO meeting

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Low-fat diet reduces risk of heart disease

IV ibuprofen effective in reducing fever in hospitalized patients

Vanderbilt-Ingram Cancer Center receives $7.6M ARRA stimulus grant for prostate cancer research

Phase 3 study of D-tagatose in Type 2 diabetes shows significant reduction in HbA1c levels

Researchers identify molecular mechanism that regulate metastasis of melanoma cells

Intestinal bacteria send signals that promote cell proliferation in Wnt signaling pathway

Novel peptide NX002 demonstrates efficacy in animal model of oral mucositis: Study

New imaging technique may help in early detection of prostate cancer

Genzyme board of directors vote to reject tender offer from Sanofi-Aventis

Websites bridge gaps between patients and doctors and marketers

Parkinson’s disease pathology breakthrough

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Cs-131 brachytherapy seed implant can treat metastasized cancer

Study shows radioembolisation with TheraSphere effective for primary liver cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News